الفهرس | Only 14 pages are availabe for public view |
Abstract Hepatitis C virus (HCV) infection is strongly associated with chronic kidney disease (CKD). It is an independent risk factor for developing CKD and significantly increases morbidity and mortality in CKD patients. Recently, there have been major advancements in the treatment of HCV with the development of new direct‐ acting antivirals (DAAs). Treatment with newer direct-acting antiviral (DAA) regimens in patients with CKD is showing conflicting results as regards safety and efficacy.Despite recent advances, little is known about the effect of HCV treatment with DAAs on short and long-term kidney function. Whether or not the CKD progression can be slowed by HCV treatment has not been established. Therefore, we aimed to evaluate the impact of those two different DAA regimens on HCV infected patients with chronic kidney disease. 100 CKD patients were included , stages 3-4, receiving treatment for HCV at MASRI (faculty of Medicine Ain Shams University Research Institute), with two different DAAs regimens ( Sofosbuvir/ Daclatasvir with or without Ribavirin and Ombitasvir/Paritaprevir /Ritonavir (OMV/PTV/RTV) with Ribavirin), completed over six months follow up. Serum creatinine, eGFR (estimated glomerular filtration rate), and proteinuria were followed Summary 116 during and after treatment. Sustained virological response (SVR) was achieved in all patients. Improvement of eGFR (8-15 ml/min/1.73 m2) and proteinuria was found in both study groups. AKI (acute kidney injury) was uncommon; it occurred in three (3%) patients, out of them, two patients showed complete recovery. Adverse events were common (43%), but serious adverse events were uncommon (2%). |